BackPluristem Therapeutics Overview

Pluristem Therapeutics Current Cash

Pluristem Therapeutics's current cash is $3.4M.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$3.42M

Peer trimmed avg / median

Loading

Pluristem Therapeutics Current Cash History

Loading

Pluristem Therapeutics vs. peers: Current Cash Comparison

Loading

Pluristem Therapeutics Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Pluristem Therapeutics (PSTI) FAQ

As of the most recent data (March 2026), PSTI shows a current cash of $3.4M. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, PSTI's current cash is now $3.4M (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Pluristem Therapeutics is outperforming or lagging.

Tracking PSTI's current cash over time shows whether Pluristem Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $3.4M In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current cash page, Stockcircle has Pluristem Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current cash (currently $3.4M) with ownership activity and broader fundamentals.

Pluristem Therapeutics's current cash is $3.4M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.